share_log

Cullinan Oncology Analyst Ratings

Cullinan Oncology Analyst Ratings

庫利南腫瘤分析師評級
Benzinga Analyst Ratings ·  2022/11/21 06:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/21/2022 61.16% BTIG → $20 Initiates Coverage On → Buy
05/13/2022 101.45% SVB Leerink $36 → $25 Maintains Outperform
03/18/2022 327.07% HC Wainwright & Co. $55 → $53 Maintains Buy
06/07/2021 246.49% Morgan Stanley $40 → $43 Maintains Overweight
06/04/2021 343.19% HC Wainwright & Co. $48 → $55 Maintains Buy
06/04/2021 335.13% SVB Leerink $48 → $54 Maintains Outperform
04/27/2021 — Morgan Stanley Upgrades Equal-Weight → Overweight
04/19/2021 222.32% Morgan Stanley $38 → $40 Maintains Equal-Weight
03/30/2021 286.78% HC Wainwright & Co. $47 → $48 Maintains Buy
02/02/2021 343.19% Evercore ISI Group → $55 Initiates Coverage On → Outperform
02/02/2021 319.02% SVB Leerink → $52 Initiates Coverage On → Outperform
02/02/2021 — Morgan Stanley Initiates Coverage On → Equal-Weight
02/01/2021 278.73% HC Wainwright & Co. → $47 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
11/21/2022 61.16% BTIG → $20 開始承保 →購買
05/13/2022 101.45% SVB Leerink $36 → $25 維護 跑贏大盤
03/18/2022 327.07% HC Wainwright公司 $55 → $53 維護 買
06/07/2021 246.49% 摩根士丹利 $40 → $43 維護 超重
06/04/2021 343.19% HC Wainwright公司 $48 → $55 維護 買
06/04/2021 335.13% SVB Leerink $48 → $54 維護 跑贏大盤
04/27/2021 — 摩根士丹利 升級 等重→超重
04/19/2021 222.32% 摩根士丹利 $38 → $40 維護 等重
03/30/2021 286.78% HC Wainwright公司 $47 → $48 維護 買
02/02/2021 343.19% Evercore ISI集團 → $55 開始承保 →跑贏大盤
02/02/2021 319.02% SVB Leerink → $52 開始承保 →跑贏大盤
02/02/2021 — 摩根士丹利 開始承保 →等重
02/01/2021 278.73% HC Wainwright公司 → $47 開始承保 →購買

What is the target price for Cullinan Oncology (CGEM)?

庫利南腫瘤(CGEM)的目標價格是多少？

The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by BTIG on November 21, 2022. The analyst firm set a price target for $20.00 expecting CGEM to rise to within 12 months (a possible 61.16% upside). 3 analyst firms have reported ratings in the last year.

庫利南腫瘤學(納斯達克：CGEM)的最新目標價是由BTIG於2022年11月21日報道的。這家分析公司將目標價定為20.00美元，預計CGEM將在12個月內上漲(可能上漲61.16%)。3家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Cullinan Oncology (CGEM)?

庫利南腫瘤學(CGEM)的最新分析師評級是多少？

The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by BTIG, and Cullinan Oncology initiated their buy rating.

納斯達克(BTIG)提供了對庫利南腫瘤學的最新分析師評級，庫利南腫瘤學啟動了他們的買入評級。

When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?

庫利南腫瘤學(CGEM)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與庫利南腫瘤公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。庫利南腫瘤學的上一次評級是在2022年11月21日提交的，所以你應該預計下一次評級將在2023年11月21日左右的某個時候提供。

Is the Analyst Rating Cullinan Oncology (CGEM) correct?

分析師對庫利南腫瘤學(CGEM)的評級正確嗎？

While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a initiated with a price target of $0.00 to $20.00. The current price Cullinan Oncology (CGEM) is trading at is $12.41, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的庫利南腫瘤學(CGEM)評級是以0.00美元至20.00美元的目標價啟動的。庫利南腫瘤公司(CGEM)目前的交易價格為12.41美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論